OBJECTIVES: Pilot study to compare the effect of inhaled nitric oxide (iNO) and aerosolized iloprost in preventing perioperative pulmonary hypertensive crises (PHTCs). BACKGROUND: Guidelines recommend the use of iNO to treat PHTCs, but treatment with iNO is not an ideal vasodilator. Aerosolized iloprost may be a possible alternative to iNO in this setting. METHODS: Investigator-initiated, open-label, randomized clinical trial in 15 infants (age range 77-257 days) with left-to-right shunt (11 out of 15 with additional trisomy 21), and pulmonary hypertension (i.e. mean pulmonary artery pressure [PAP] >25 mmHg) after weaning from cardiopulmonary bypass. Patients were randomized to treatment with iNO at 10 ppm or aerosolized iloprost at 0.5 µg/kg (every 2 h). The observation period was 72 h after weaning from cardiopulmonary bypass. The primary endpoint was the occurrence of PHTCs; the secondary endpoints were mean PAP, duration of mechanical ventilation, safety of administration, and in-hospital mortality. RESULTS: Seven patients received iNO and eight patients received iloprost. During the observation period, 13 of the 15 patients had at least one major or minor PHTC. There was no difference between the groups with regard to the frequency of PHTCs, mean PAP and duration of mechanical ventilation (p > 0.05). CONCLUSIONS: In this pilot study, aerosolized iloprost had a favorable safety profile. Larger trials are needed to compare its efficacy to iNO for the treatment of perioperative pulmonary hypertension. However, neither treatment alone abolished the occurrence of PHTCs.
RCT Entities:
OBJECTIVES: Pilot study to compare the effect of inhaled nitric oxide (iNO) and aerosolized iloprost in preventing perioperative pulmonary hypertensive crises (PHTCs). BACKGROUND: Guidelines recommend the use of iNO to treat PHTCs, but treatment with iNO is not an ideal vasodilator. Aerosolized iloprost may be a possible alternative to iNO in this setting. METHODS: Investigator-initiated, open-label, randomized clinical trial in 15 infants (age range 77-257 days) with left-to-right shunt (11 out of 15 with additional trisomy 21), and pulmonary hypertension (i.e. mean pulmonary artery pressure [PAP] >25 mmHg) after weaning from cardiopulmonary bypass. Patients were randomized to treatment with iNO at 10 ppm or aerosolized iloprost at 0.5 µg/kg (every 2 h). The observation period was 72 h after weaning from cardiopulmonary bypass. The primary endpoint was the occurrence of PHTCs; the secondary endpoints were mean PAP, duration of mechanical ventilation, safety of administration, and in-hospital mortality. RESULTS: Seven patients received iNO and eight patients received iloprost. During the observation period, 13 of the 15 patients had at least one major or minor PHTC. There was no difference between the groups with regard to the frequency of PHTCs, mean PAP and duration of mechanical ventilation (p > 0.05). CONCLUSIONS: In this pilot study, aerosolized iloprost had a favorable safety profile. Larger trials are needed to compare its efficacy to iNO for the treatment of perioperative pulmonary hypertension. However, neither treatment alone abolished the occurrence of PHTCs.
Authors: P C Rimensberger; I Spahr-Schopfer; M Berner; E Jaeggi; A Kalangos; B Friedli; M Beghetti Journal: Circulation Date: 2001-01-30 Impact factor: 29.690
Authors: K Bando; P Vijayaraghavan; M W Turrentine; T G Sharp; G J Ensing; Y Sekine; L Szekely; R J Morelock; J W Brown Journal: Circulation Date: 1997-11-04 Impact factor: 29.690
Authors: K Bando; M W Turrentine; T G Sharp; Y Sekine; T X Aufiero; K Sun; E Sekine; J W Brown Journal: J Thorac Cardiovasc Surg Date: 1996-12 Impact factor: 5.209
Authors: S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: D Dunbar Ivy; Aimee K Doran; Kelly J Smith; George B Mallory; Maurice Beghetti; Robyn J Barst; Daniela Brady; Yuk Law; Donna Parker; Lori Claussen; Steven H Abman Journal: J Am Coll Cardiol Date: 2008-01-15 Impact factor: 24.094
Authors: Robert M DiBlasi; Dave N Crotwell; Shuijie Shen; Jiang Zheng; James B Fink; Delphine Yung Journal: Pulm Circ Date: 2016-03 Impact factor: 3.017
Authors: Ana Maria Thomaz; Luiz Junya Kajita; Vera D Aiello; Leína Zorzanelli; Filomena Rbg Galas; Cleide G Machado; Miguel Barbero-Marcial; Marcelo B Jatene; Marlene Rabinovitch; Antonio Augusto Lopes Journal: Pulm Circ Date: 2019-02-26 Impact factor: 3.017
Authors: T Baehner; O Boehm; M Kliemann; I Heinze; J Breuer; A Hoeft; G Baumgarten; P Knuefermann Journal: Anaesthesist Date: 2015-06 Impact factor: 1.041
Authors: Nathan Brunner; Vinicio A de Jesus Perez; Alice Richter; François Haddad; André Denault; Vanessa Rojas; Ke Yuan; Mark Orcholski; Xiaobo Liao Journal: Pulm Circ Date: 2014-03 Impact factor: 3.017